Last reviewed · How we verify
Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY
Approved treatments
- BNT162b2 (Omi XBB.1.5)/RIV · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY treatment landscape brief
- Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY treatment updates RSS
Frequently asked questions about Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY
What drugs treat Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY?
Tracked treatments include BNT162b2 (Omi XBB.1.5)/RIV.
What is the treatment for Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY?
Standard treatment for Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY includes BNT162b2 (Omi XBB.1.5)/RIV. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY patent cliff · Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY CI report
- Treatment: BNT162b2 (Omi XBB.1.5)/RIV · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing